Publications by authors named "Chiara Contri"

Claim this Profile
N
New Vanillyl-capped HDAC inhibitors exhibit anti-tumor efficacy in neuroblastoma and glioblastoma cells.
Ilaria Cursaro, Luca Frattaruolo, Laura Scalvini, Chiara Contri, Alessia Bichicchi

Bioorg Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncovering a Mutation-Independent Therapeutic Strategy against Inherited Retinal Diseases: Development of Class I HDAC/LSD1 Hybrid Inhibitors.
Gabriele Carullo, Ilaria Piano, Giulia Salamone, Francesca Corsi, Noemi Orsini, Chiara Contri

ACS Chem Neurosci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients.
Anna Fontana, Laura Bergantini, Gabriele Carullo, Laura Scalvini, Miriana D'Alessandro, Chiara Contri

ACS Pharmacol Transl Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy.
Gabriele Carullo, Noemi Orsini, Ilaria Piano, Luca Pozzetti, Alessandro Papa, Chiara Contri

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies.
Gabriele Carullo, Sara Rossi, Valentina Giudice, Alex Pezzotta, Ugo Chianese, Chiara Contri

ACS Pharmacol Transl Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence.
Annalida Bedini, Gian Marco Elisi, Fabiola Fanini, Michele Retini, Laura Scalvini, Chiara Contri

J Pineal Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents.
Alessandro Papa, Ilaria Cursaro, Luca Pozzetti, Chiara Contri, Martina Cappello

Arch Pharm (Weinheim)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of Adenosine Receptors: Recent Advancements.
Fabrizio Vincenzi, Silvia Pasquini, Chiara Contri, Martina Cappello, Manuela Nigro

Biomolecules· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caffeine for Prevention of Alzheimer's Disease: Is the A Adenosine Receptor Its Target?
Stefania Merighi, Alessia Travagli, Manuela Nigro, Silvia Pasquini, Martina Cappello, Chiara Contri

Biomolecules· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions.
Alessandro Papa, Silvia Pasquini, Francesca Galvani, Mariarosaria Cammarota, Chiara Contri

Eur J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells.
Gabriele Carullo, Laura Bottoni, Silvia Pasquini, Alessandro Papa, Chiara Contri

ChemMedChem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications.
Silvia Pasquini, Chiara Contri, Martina Cappello, Pier Andrea Borea, Katia Varani

Front Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition.
Alessandro Papa, Silvia Pasquini, Chiara Contri, Sandra Gemma, Giuseppe Campiani

Cells· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.
Silvia Pasquini, Chiara Contri, Stefania Merighi, Stefania Gessi, Pier Andrea Borea

Int J Mol Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenosine and Inflammation: Here, There and Everywhere.
Silvia Pasquini, Chiara Contri, Pier Andrea Borea, Fabrizio Vincenzi, Katia Varani

Int J Mol Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis